Genscript Biotech Corporation (G51) — Cash Flow-to-Debt Ratio
Genscript Biotech Corporation (G51) has a Cash Flow-to-Debt Ratio of -0.07x as of June 2023, meaning its operating cash flow of €-93.58 Million could theoretically repay 0% of its total liabilities (€1.30 Billion) in one year. Check Genscript Biotech Corporation (G51) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Genscript Biotech Corporation Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Genscript Biotech Corporation across 10 annual periods. Also explore how large is Genscript Biotech Corporation's balance sheet for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Genscript Biotech Corporation (2016–2025)
Year-by-year debt coverage analysis for Genscript Biotech Corporation. For market capitalisation and broader financial context, see G51 market cap.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.37x | €325.52 Million | €888.59 Million | ▲ +362.4% |
| 2024 | 0.08x | €75.65 Million | €954.91 Million | ▲ +137.1% |
| 2023 | -0.21x | €-286.91 Million | €1.34 Billion | ▼ -110.2% |
| 2022 | -0.10x | €-120.29 Million | €1.18 Billion | ▲ +15.3% |
| 2021 | -0.12x | €-136.79 Million | €1.14 Billion | ▲ +49.8% |
| 2020 | -0.24x | €-151.09 Million | €631.82 Million | ▼ -312.8% |
| 2019 | -0.06x | €-29.95 Million | €517.11 Million | ▼ -108.0% |
| 2018 | 0.73x | €307.66 Million | €423.68 Million | ▲ +837.8% |
| 2017 | 0.08x | €21.37 Million | €275.94 Million | ▼ -90.2% |
| 2016 | 0.79x | €33.27 Million | €42.01 Million | — |